Ads
related to: median survival metastatic prostate cancer- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Schedule an Appointment
Schedule an Appointment Today
Call our Cancer Answer Line
- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Prostate Cancer Treatment
Search results
Results from the WOW.Com Content Network
James, Sydes & Clarke 2016 reported that "the addition of docetaxel to standard of care was associated with improved survival, with an HR of 0·78 and a difference in median survival of 10 months, as well as improvements in prostate-cancer-specific survival, failure-free survival, and skeletal-related events".
Several types of cancer are associated with high survival rates, including breast, prostate, testicular and colon cancer. Brain and pancreatic cancers have much lower median survival rates which have not improved as dramatically over the last forty years. [4] Indeed, pancreatic cancer has one of the worst survival rates of all cancers.
Prostate cancer is a major topic of ongoing research. From 2016–2020, over $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. [122] This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost. [123]
In fact, the ACS puts the five-year survival rate for local and regionalized prostate cancer at about 99%. Understanding your risk and signs and symptoms of prostate cancer can be life-saving ...
In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for participants receiving cabazitaxel versus 12.7 months for participants receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%). [13]
Conversely, it was not effective for localized prostate cancer, where there was instead a statistically insignificant trend toward reduced overall survival with bicalutamide therapy (at median 7.4 years follow-up: HR Tooltip hazard ratio = 1.16; 95% CI Tooltip confidence interval = 0.99–1.37; P Tooltip p-value = 0.07).
Ads
related to: median survival metastatic prostate cancer